Abstract
Background: Dyslipidemia is a common comorbidity and an important risk factor for myocardial infarction (MI). This study aimed to examine the economic burden of MI combined with dyslipidemia in China.Methods: Patients who were hospitalized due to MI combined with dyslipidemia in 2016 were enrolled. Costs were measured based on electronic medical records and questionnaires. The annual costs were analyzed by conducting descriptive statistics, univariable, and multivariable analyses.Results: Data of 900 patients were analyzed, and 144 patients were dead during the follow-up. The majority of patients were aged 51–70 years (n = 563, 62.55%) and males (n = 706, 78.44%). For all-cause costs, the median annual direct medical costs, direct non-medical costs, indirect costs, and total costs were RMB 13,168 (5,212–29,369), RMB 600 (0–1,750), RMB 676 (0–1,787), RMB 15,361 (6,440–33,943), respectively; while for cardiovascular-related costs, the corresponding costs were RMB 12,233 (3,795–23,746), RMB 515 (0–1,680), RMB 587 (0–1,655), and RMB 14,223 (4,914–28,975), respectively. Lifestyle and complications significantly affected both all-cause costs and cardiovascular-related costs.Conclusions: Increasing attention should be paid to encourage healthy lifestyle, and evidence-based medicine should focus on optimal precautions and treatments for complications, to reduce the economic burden among MI patients with a comorbid dyslipidemia.
Highlights
There are ∼290 million cardiovascular patients in China, including 11 million patients with coronary atherosclerotic heart disease, in which myocardial infarction (MI) is the most acute and dangerous disease [1]
94.67% (n = 852) patients were of first-episode MI, 64.67% (n = 582) had undergone postpercutaneous transluminal coronary intervention (PCI), and most complications were hypertension (n = 537, 59.67%), type 2 diabetes (n = 276, 30.67%), and lipid metabolism disorder (n = 269, 29.89%)
Our investigation is the first study to investigate the costs of patients with MI combined with dyslipidemia in China from the whole society’s perspective using the real-world data in China
Summary
There are ∼290 million cardiovascular patients in China, including 11 million patients with coronary atherosclerotic heart disease, in which myocardial infarction (MI) is the most acute and dangerous disease [1]. Cardiovascular diseases have long been the leading cause of death among Chinese residents, while the mortality rate of MI in China had been on the rise from 2002 to 2016, since 2005. It is estimated that elevated serum cholesterol levels will cause 9.2 million patients with cardiovascular disease (CVD) from 2010 to 2030 [9]. Dyslipidemia is a common comorbidity and an important risk factor for myocardial infarction (MI). This study aimed to examine the economic burden of MI combined with dyslipidemia in China
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
